首页> 外文OA文献 >Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years

【2h】

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years

机译：长期治疗粘附于Proprotein转化酶枯草杆菌蛋白酶/ kexin型9型抑制剂Alirocumab在6个奥德赛期III临床研究中，治疗持续时间为1至2年

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Michel Farnier; Helen M. Colhoun; William J. Sasiela; Jay M. Edelberg; Gaëlle Asset; Jennifer G. Robinson;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with: treatment duration of 1 to 2 years [J] . Farnier Michel, Colhoun Helen M., Sasiela William J., Journal of clinical lipidology . 2017,第4期

机译：长期治疗粘附于Proprotein转化酶枯草杆菌蛋白酶/ kexin型9抑制剂Alirocumab在6个奥德赛期III临床研究中：治疗持续时间为1至2年
2. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study [J] . Kereiakes Dean J., Robinson Jennifer G., Cannon Christopher P., The American heart journal . 2015,第6期

机译：ODYSSEY COMBO I研究在高耐受性他汀类药物治疗的高心血管风险患者中前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型抑制剂alirocumab的疗效和安全性
3. Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin/kexin type 9 inhibitor, alirocumab (Praluent) [J] . Mohamed K.M. Shakir, Terry Shin, Thanh D. Hoang, Journal of clinical lipidology . 2017,第6期

机译：用Proprotein转化酶枯草杆菌蛋白酶/ kexin型9型患者的患者患有他汀类药物病变和肌肌营养不良症II型患者的患者，Alirocumab（术语）
4. Minimally invasive treatment of Benign Prostatic Hyperplasia with High Intensity Focused Ultrasound using the Sonablate~(TM) System: an updated report of Phase III clinical studies conducted in the USA [C] . Thomas A. Gardner, Michael O Koch, Arieh Shalhav, Conference on Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems Ⅻ Jan 19-20, 22, 2002 San Jose, USA . 2002

机译：使用Sonablate〜（TM）系统以高强度聚焦超声微创治疗良性前列腺增生：在美国进行的III期临床研究的最新报告
5. Evaluation of the Interaction Between Proprotein Convertase Subtilisin/Kexin Type 9 and Sterol Carrier Protein-2 [D] . Ahranjani, Reza. 2017

机译：评价前蛋白转化酶枯草杆菌蛋白酶/ Kexin 9型与甾醇载体蛋白2的相互作用。
6. Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study [O] . Jakob Solgaard Jensen, Peter Ejvin Weeke, Lia Evi Bang, 2019

机译：一项针对全国性队列研究的前蛋白转化酶枯草杆菌蛋白酶-kexin 9型抑制剂引发的患者的临床特征和降脂治疗
7. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy:the ODYSSEY COMBO I study [O] . Kereiakes, Dean J., Robinson, Jennifer G., Cannon, Christopher P., 2015

机译：高度耐受他汀类药物治疗的高心血管风险患者中前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型抑制剂alirocumab的疗效和安全性：ODYSSEY COMBO I研究

Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years

著录项

相似文献

相关主题

期刊订阅